Literature DB >> 11703563

Contribution of CYP1A2 in the hepatic metabolism of melatonin: studies with isolated microsomal preparations and liver slices.

D J Skene1, E Papagiannidou, E Hashemi, J Snelling, D F Lewis, M Fernandez, C Ioannides.   

Abstract

The objective of the present studies was to define the enzyme systems catalysing the 6-hydroxylation of melatonin, by monitoring the levels of 6-sulphatoxymelatonin in rat hepatic postmitochondrial preparations and in precision-cut liver slices. Melatonin 6-hydroxylase activity was localized in microsomes and was supported by NADPH, but not NADH. Treatment of rats with beta-naphthoflavone more than tripled 6-sulphatoxymelatonin formation from melatonin, but gave rise only to a moderate increase (25%) in the sulphate conjugation of 6-hydroxymelatonin. Treatment of rats with phenobarbitone, acetone, dexamethasone and clofibrate did not increase 6-sulphatoxymelatonin generation when either melatonin or 6-hydroxymelatonin served as substrates. Of a number of cytochrome P450 inhibitors investigated, only furafylline inhibited markedly the conversion of melatonin to 6-sulphatoxymelatonin without any concomitant effect on the sulphoconjugation of 6-hydroxymelatonin. When liver slices were incubated with melatonin, treatment of rats with beta-naphthoflavone, and to a lesser extent phenobarbitone, elevated the levels of 6-sulphatoxymelatonin in the culture medium. No such increase was seen when slices from beta-naphthoflavone-treated rats were incubated with 6-hydroxymelatonin, whereas a modest increase was seen with slices from phenobarbitone-treated rats. Treatment of rats with acetone, dexamethasone or clofibrate failed to modulate the levels of 6-sulphatoxymelatonin generated from either melatonin or 6-hydroxymelatonin. Molecular modelling analysis revealed that melatonin had a high area/depth(2) ratio, displayed characteristics of CYP1A2 substrates and could be readily accommodated into the human CYP1A2 active site in a position favouring 6-hydroxylation. Collectively, all the above data provide strong experimental evidence that CYP1A2 is an important catalyst of the 6-hydroxylation of melatonin.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11703563     DOI: 10.1034/j.1600-079x.2001.310408.x

Source DB:  PubMed          Journal:  J Pineal Res        ISSN: 0742-3098            Impact factor:   13.007


  14 in total

1.  Effects of Caffeic Acid and Quercetin on In Vitro Permeability, Metabolism and In Vivo Pharmacokinetics of Melatonin in Rats: Potential for Herb-Drug Interaction.

Authors:  Snehasis Jana; Himanshu Rastogi
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2017-10       Impact factor: 2.441

Review 2.  Potential role of CYP1B1 in the development and treatment of metabolic diseases.

Authors:  Fei Li; Weifeng Zhu; Frank J Gonzalez
Journal:  Pharmacol Ther       Date:  2017-03-16       Impact factor: 12.310

Review 3.  Insights into the substrate specificity, inhibitors, regulation, and polymorphisms and the clinical impact of human cytochrome P450 1A2.

Authors:  Shu-Feng Zhou; Li-Ping Yang; Zhi-Wei Zhou; Ya-He Liu; Eli Chan
Journal:  AAPS J       Date:  2009-07-10       Impact factor: 4.009

Review 4.  The role of melatonin in tomato stress response, growth and development.

Authors:  Qiaoli Xie; Yu Zhang; Yingxia Cheng; Yanling Tian; Junjie Luo; Zongli Hu; Guoping Chen
Journal:  Plant Cell Rep       Date:  2022-05-16       Impact factor: 4.964

Review 5.  Cytochromes p450 and skin cancer: role of local endocrine pathways.

Authors:  Andrzej T Slominski; Michal A Zmijewski; Igor Semak; Blazej Zbytek; Alexander Pisarchik; Wei Li; Jordan Zjawiony; Robert C Tuckey
Journal:  Anticancer Agents Med Chem       Date:  2014-01       Impact factor: 2.505

6.  Melatonin protects from, but does not reverse, the effects of mediators of sepsis on liver bioenergetics.

Authors:  Marina Basile; Carmelo Romeo; Eloisa Gitto; Lewis Spitz; Agostino Pierro; Simon Eaton
Journal:  Pediatr Surg Int       Date:  2004-02-04       Impact factor: 1.827

7.  Metabolism of melatonin by cytochrome P450s in rat liver mitochondria and microsomes.

Authors:  Igor Semak; Elena Korik; Maria Antonova; Jacobo Wortsman; Andrzej Slominski
Journal:  J Pineal Res       Date:  2008-08-19       Impact factor: 13.007

8.  Fatigued Patients with Chronic Liver Disease Have Subtle Aberrations of Sleep, Melatonin and Cortisol Circadian Rhythms.

Authors:  Michele M Tana; Hawwa Alao; Nevitt Morris; Shanna Bernstein; Jacob Hattenbach; Rahiya B Rehman; Robert Brychta; Souvik Sarkar; Xiongce Zhao; Mary Walter; Ashura Buckley; Kong Chen; Yaron Rotman
Journal:  Fatigue       Date:  2017-12-03

Review 9.  Melatonin Therapy in Patients with Alzheimer's Disease.

Authors:  Daniel P Cardinali; Daniel E Vigo; Natividad Olivar; María F Vidal; Luis I Brusco
Journal:  Antioxidants (Basel)       Date:  2014-04-10

Review 10.  Kynurenic Acid: The Janus-Faced Role of an Immunomodulatory Tryptophan Metabolite and Its Link to Pathological Conditions.

Authors:  Elisa Wirthgen; Andreas Hoeflich; Alexander Rebl; Juliane Günther
Journal:  Front Immunol       Date:  2018-01-10       Impact factor: 7.561

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.